| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antibodies, Monoclonal | 64 | 2026 | 875 | 4.840 |
Why?
|
| HIV Antibodies | 36 | 2018 | 146 | 4.260 |
Why?
|
| HIV-1 | 42 | 2018 | 710 | 3.490 |
Why?
|
| Immunoglobulin A | 10 | 2026 | 102 | 2.940 |
Why?
|
| Antibodies, Neutralizing | 10 | 2026 | 220 | 1.950 |
Why?
|
| HIV Envelope Protein gp120 | 25 | 2018 | 130 | 1.930 |
Why?
|
| Antibodies, Bacterial | 17 | 2026 | 181 | 1.770 |
Why?
|
| HIV Infections | 24 | 2018 | 961 | 1.770 |
Why?
|
| Epitopes | 24 | 2026 | 291 | 1.720 |
Why?
|
| Lyme Disease | 9 | 2026 | 123 | 1.640 |
Why?
|
| Enterotoxigenic Escherichia coli | 7 | 2023 | 22 | 1.600 |
Why?
|
| Borrelia burgdorferi | 8 | 2026 | 93 | 1.500 |
Why?
|
| Single-Domain Antibodies | 4 | 2026 | 21 | 1.470 |
Why?
|
| Immunoglobulin G | 22 | 2024 | 472 | 1.440 |
Why?
|
| Immunoglobulin Fc Fragments | 3 | 2026 | 50 | 1.310 |
Why?
|
| Immunoglobulin A, Secretory | 6 | 2023 | 22 | 1.200 |
Why?
|
| Bacterial Outer Membrane Proteins | 10 | 2026 | 127 | 1.200 |
Why?
|
| Antibody Specificity | 8 | 2020 | 103 | 1.170 |
Why?
|
| Neutralization Tests | 30 | 2018 | 126 | 1.120 |
Why?
|
| HIV Envelope Protein gp41 | 9 | 2016 | 27 | 0.950 |
Why?
|
| Receptors, Fc | 4 | 2024 | 25 | 0.880 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2026 | 503 | 0.870 |
Why?
|
| Lipoproteins | 6 | 2026 | 85 | 0.750 |
Why?
|
| Antibodies, Bispecific | 2 | 2016 | 33 | 0.720 |
Why?
|
| Pemphigus | 4 | 2016 | 14 | 0.710 |
Why?
|
| Autoantibodies | 4 | 2016 | 186 | 0.700 |
Why?
|
| Escherichia coli Infections | 6 | 2023 | 90 | 0.690 |
Why?
|
| CD4 Antigens | 14 | 2013 | 149 | 0.640 |
Why?
|
| Lyme Disease Vaccines | 6 | 2026 | 10 | 0.630 |
Why?
|
| Animals | 56 | 2026 | 21493 | 0.620 |
Why?
|
| Mice | 34 | 2026 | 11185 | 0.620 |
Why?
|
| Antigens, Surface | 8 | 2026 | 199 | 0.620 |
Why?
|
| Peptide Fragments | 7 | 2009 | 419 | 0.590 |
Why?
|
| Bacterial Vaccines | 6 | 2026 | 79 | 0.590 |
Why?
|
| Desmoglein 3 | 3 | 2016 | 6 | 0.570 |
Why?
|
| HIV | 4 | 2013 | 67 | 0.570 |
Why?
|
| Immunization, Passive | 12 | 2023 | 97 | 0.560 |
Why?
|
| Antigens, Bacterial | 5 | 2026 | 202 | 0.550 |
Why?
|
| Immunoglobulin Fab Fragments | 7 | 2025 | 33 | 0.520 |
Why?
|
| Epitopes, B-Lymphocyte | 4 | 2025 | 18 | 0.510 |
Why?
|
| Humans | 84 | 2026 | 65845 | 0.510 |
Why?
|
| Caulobacter crescentus | 3 | 2013 | 36 | 0.500 |
Why?
|
| Immunoglobulin Isotypes | 3 | 2012 | 24 | 0.490 |
Why?
|
| Single-Chain Antibodies | 1 | 2016 | 5 | 0.490 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 256 | 0.480 |
Why?
|
| Antibodies, Viral | 6 | 2026 | 329 | 0.480 |
Why?
|
| Anti-HIV Agents | 4 | 2013 | 139 | 0.470 |
Why?
|
| Escherichia coli Vaccines | 3 | 2021 | 11 | 0.460 |
Why?
|
| Immunoglobulin Variable Region | 7 | 2007 | 34 | 0.460 |
Why?
|
| Spike Glycoprotein, Coronavirus | 4 | 2026 | 114 | 0.450 |
Why?
|
| Neutrophils | 3 | 2025 | 396 | 0.430 |
Why?
|
| Binding Sites, Antibody | 4 | 2012 | 21 | 0.430 |
Why?
|
| Antigens, CD | 5 | 2016 | 344 | 0.420 |
Why?
|
| Ticks | 3 | 2023 | 36 | 0.410 |
Why?
|
| Immunoglobulin Constant Regions | 1 | 2012 | 8 | 0.380 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2023 | 449 | 0.380 |
Why?
|
| Milk | 2 | 2013 | 47 | 0.380 |
Why?
|
| Simian Immunodeficiency Virus | 8 | 2011 | 84 | 0.380 |
Why?
|
| Epitope Mapping | 7 | 2025 | 52 | 0.360 |
Why?
|
| AIDS Vaccines | 6 | 2011 | 73 | 0.350 |
Why?
|
| Diarrhea | 3 | 2021 | 75 | 0.350 |
Why?
|
| Virion | 5 | 2016 | 122 | 0.330 |
Why?
|
| Tuberculosis | 2 | 2025 | 314 | 0.330 |
Why?
|
| Membrane Glycoproteins | 5 | 2013 | 667 | 0.330 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2025 | 424 | 0.320 |
Why?
|
| Cell Line | 13 | 2021 | 2031 | 0.310 |
Why?
|
| Immunoglobulins | 1 | 2010 | 74 | 0.310 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 7 | 2011 | 62 | 0.290 |
Why?
|
| Camelids, New World | 2 | 2026 | 10 | 0.280 |
Why?
|
| Protein Engineering | 2 | 2026 | 85 | 0.280 |
Why?
|
| Malaria | 5 | 1990 | 159 | 0.270 |
Why?
|
| Immunoglobulin Class Switching | 2 | 2007 | 82 | 0.250 |
Why?
|
| Adhesins, Bacterial | 1 | 2025 | 10 | 0.230 |
Why?
|
| Protein Multimerization | 2 | 2020 | 181 | 0.220 |
Why?
|
| Gene Products, env | 2 | 2003 | 18 | 0.220 |
Why?
|
| Glucuronic Acid | 1 | 2004 | 20 | 0.220 |
Why?
|
| Hexuronic Acids | 1 | 2004 | 23 | 0.220 |
Why?
|
| Antibody Affinity | 3 | 2021 | 18 | 0.220 |
Why?
|
| Immunity, Cellular | 6 | 2010 | 170 | 0.210 |
Why?
|
| Pseudomonas Infections | 1 | 2004 | 73 | 0.210 |
Why?
|
| Glycosylation | 5 | 2021 | 139 | 0.200 |
Why?
|
| Immunodominant Epitopes | 2 | 2008 | 59 | 0.200 |
Why?
|
| Virus Replication | 1 | 2005 | 323 | 0.200 |
Why?
|
| Cell Membrane | 3 | 2002 | 506 | 0.200 |
Why?
|
| HIV Antigens | 1 | 2003 | 18 | 0.200 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2004 | 132 | 0.200 |
Why?
|
| Cricetulus | 3 | 2019 | 104 | 0.190 |
Why?
|
| Protein Binding | 4 | 2025 | 1638 | 0.190 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 3 | 2016 | 29 | 0.190 |
Why?
|
| CHO Cells | 3 | 2019 | 193 | 0.190 |
Why?
|
| Borrelia burgdorferi Group | 1 | 2022 | 30 | 0.180 |
Why?
|
| Immunoglobulin Heavy Chains | 4 | 1998 | 47 | 0.180 |
Why?
|
| Mice, SCID | 4 | 2018 | 518 | 0.180 |
Why?
|
| Immunity, Humoral | 2 | 2014 | 40 | 0.180 |
Why?
|
| Recombinant Proteins | 4 | 2011 | 710 | 0.180 |
Why?
|
| Chemokine CCL3 | 2 | 2013 | 8 | 0.180 |
Why?
|
| Crystallography, X-Ray | 5 | 2025 | 415 | 0.180 |
Why?
|
| Plasmodium | 4 | 1990 | 34 | 0.170 |
Why?
|
| Cancer Vaccines | 1 | 2002 | 51 | 0.170 |
Why?
|
| Prostate-Specific Antigen | 1 | 2002 | 85 | 0.170 |
Why?
|
| Chlamydia trachomatis | 1 | 2021 | 60 | 0.170 |
Why?
|
| Cervix Uteri | 1 | 2021 | 58 | 0.170 |
Why?
|
| Molecular Sequence Data | 9 | 2011 | 1980 | 0.170 |
Why?
|
| Cross Reactions | 7 | 2020 | 140 | 0.170 |
Why?
|
| Chlamydia Infections | 1 | 2021 | 79 | 0.170 |
Why?
|
| Herpesvirus 4, Human | 2 | 1999 | 199 | 0.160 |
Why?
|
| Macaca mulatta | 9 | 2021 | 263 | 0.160 |
Why?
|
| Chromatography, Affinity | 1 | 2020 | 52 | 0.160 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2020 | 45 | 0.160 |
Why?
|
| Escherichia coli Proteins | 2 | 2021 | 278 | 0.160 |
Why?
|
| Cricetinae | 2 | 2013 | 362 | 0.150 |
Why?
|
| Keratinocytes | 3 | 2016 | 76 | 0.150 |
Why?
|
| Administration, Oral | 6 | 2023 | 371 | 0.140 |
Why?
|
| T-Lymphocytes | 6 | 1993 | 1012 | 0.140 |
Why?
|
| Gastrointestinal Tract | 1 | 2020 | 187 | 0.140 |
Why?
|
| Antigen-Antibody Reactions | 3 | 2010 | 13 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 182 | 0.140 |
Why?
|
| Amino Acid Sequence | 8 | 2009 | 1590 | 0.140 |
Why?
|
| Disease Models, Animal | 8 | 2021 | 2329 | 0.140 |
Why?
|
| Animals, Genetically Modified | 1 | 2018 | 312 | 0.130 |
Why?
|
| Head and Neck Neoplasms | 3 | 2005 | 166 | 0.130 |
Why?
|
| Viral Envelope Proteins | 2 | 2016 | 102 | 0.130 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 526 | 0.130 |
Why?
|
| Models, Molecular | 7 | 2023 | 1161 | 0.130 |
Why?
|
| Polymers | 1 | 2020 | 332 | 0.130 |
Why?
|
| Cells, Cultured | 3 | 2016 | 2194 | 0.130 |
Why?
|
| Prostatic Neoplasms | 1 | 2002 | 504 | 0.130 |
Why?
|
| Structure-Activity Relationship | 3 | 2010 | 357 | 0.130 |
Why?
|
| Female | 20 | 2024 | 34425 | 0.120 |
Why?
|
| Acquired Immunodeficiency Syndrome | 5 | 2001 | 129 | 0.120 |
Why?
|
| Exfoliatins | 1 | 2016 | 1 | 0.120 |
Why?
|
| Antibody Formation | 2 | 2016 | 111 | 0.120 |
Why?
|
| Genes, Immunoglobulin | 4 | 2003 | 33 | 0.120 |
Why?
|
| Complementarity Determining Regions | 2 | 2014 | 33 | 0.120 |
Why?
|
| CD4 Lymphocyte Count | 6 | 2006 | 92 | 0.120 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2016 | 29 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 5 | 2003 | 426 | 0.110 |
Why?
|
| Ebolavirus | 1 | 2016 | 39 | 0.110 |
Why?
|
| Transplantation, Heterologous | 2 | 1992 | 241 | 0.110 |
Why?
|
| Base Sequence | 5 | 2006 | 1332 | 0.110 |
Why?
|
| Microscopy, Fluorescence | 1 | 2016 | 401 | 0.110 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 1292 | 0.110 |
Why?
|
| Animals, Newborn | 6 | 2006 | 241 | 0.110 |
Why?
|
| Nanoparticles | 1 | 2020 | 553 | 0.100 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2001 | 248 | 0.100 |
Why?
|
| Hybridomas | 2 | 2004 | 63 | 0.100 |
Why?
|
| Phagocytosis | 2 | 2006 | 257 | 0.100 |
Why?
|
| Genetic Engineering | 2 | 2013 | 114 | 0.100 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 2007 | 111 | 0.100 |
Why?
|
| Infectious Disease Transmission, Vertical | 5 | 2003 | 80 | 0.100 |
Why?
|
| Antibodies, Protozoan | 2 | 1990 | 59 | 0.100 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 1992 | 138 | 0.100 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2006 | 34 | 0.100 |
Why?
|
| Lymphocyte Transfusion | 1 | 1992 | 37 | 0.090 |
Why?
|
| B-Lymphocytes | 3 | 2006 | 565 | 0.090 |
Why?
|
| Skin | 1 | 2016 | 436 | 0.090 |
Why?
|
| CD40 Antigens | 2 | 2005 | 59 | 0.090 |
Why?
|
| Virus Internalization | 1 | 2013 | 91 | 0.090 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1992 | 75 | 0.090 |
Why?
|
| Immunity, Innate | 3 | 2025 | 829 | 0.090 |
Why?
|
| Plasmids | 1 | 2013 | 294 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 3 | 2008 | 672 | 0.090 |
Why?
|
| Mammals | 2 | 2023 | 222 | 0.080 |
Why?
|
| Immunotherapy | 2 | 2021 | 274 | 0.080 |
Why?
|
| Caco-2 Cells | 2 | 2021 | 67 | 0.080 |
Why?
|
| Gene Expression | 2 | 2013 | 856 | 0.080 |
Why?
|
| Male | 13 | 2024 | 31410 | 0.080 |
Why?
|
| Cloning, Molecular | 2 | 2003 | 387 | 0.080 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 2010 | 13 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2005 | 264 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 3 | 2025 | 3506 | 0.080 |
Why?
|
| Organ Specificity | 1 | 2010 | 201 | 0.070 |
Why?
|
| Macrophage Activation | 1 | 1989 | 115 | 0.070 |
Why?
|
| Leukocytes | 1 | 1989 | 110 | 0.070 |
Why?
|
| Immune Evasion | 1 | 2009 | 71 | 0.070 |
Why?
|
| Amino Acid Substitution | 3 | 2021 | 238 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 2 | 2021 | 417 | 0.070 |
Why?
|
| Macaca fascicularis | 2 | 2021 | 48 | 0.070 |
Why?
|
| Protein Conformation | 3 | 2009 | 793 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2011 | 333 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 6 | 2006 | 869 | 0.070 |
Why?
|
| Species Specificity | 3 | 2004 | 344 | 0.070 |
Why?
|
| Acute Disease | 2 | 2004 | 665 | 0.060 |
Why?
|
| Blotting, Western | 4 | 2006 | 611 | 0.060 |
Why?
|
| Sequence Alignment | 2 | 2008 | 302 | 0.060 |
Why?
|
| Binding Sites | 5 | 2009 | 922 | 0.060 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2007 | 252 | 0.060 |
Why?
|
| Acetylglucosamine | 1 | 2006 | 11 | 0.060 |
Why?
|
| Immunity, Mucosal | 3 | 2002 | 53 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 2739 | 0.060 |
Why?
|
| HeLa Cells | 1 | 2007 | 541 | 0.060 |
Why?
|
| Immunologic Factors | 1 | 2006 | 108 | 0.060 |
Why?
|
| NIH 3T3 Cells | 1 | 2005 | 99 | 0.060 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2005 | 7 | 0.060 |
Why?
|
| DNA Primers | 1 | 2005 | 302 | 0.050 |
Why?
|
| Staphylococcus aureus | 1 | 2006 | 183 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2005 | 96 | 0.050 |
Why?
|
| Mice, Inbred C3H | 1 | 2004 | 173 | 0.050 |
Why?
|
| Time Factors | 4 | 2006 | 3779 | 0.050 |
Why?
|
| Flow Cytometry | 3 | 2002 | 664 | 0.050 |
Why?
|
| Alginates | 1 | 2004 | 50 | 0.050 |
Why?
|
| Macrophages | 1 | 1989 | 1042 | 0.050 |
Why?
|
| Saliva | 1 | 2024 | 100 | 0.050 |
Why?
|
| HIV Seropositivity | 2 | 1995 | 81 | 0.050 |
Why?
|
| Drug Design | 2 | 2021 | 139 | 0.050 |
Why?
|
| Pneumonia, Bacterial | 1 | 2004 | 91 | 0.050 |
Why?
|
| Adult | 7 | 2024 | 17579 | 0.050 |
Why?
|
| Nucleocapsid Proteins | 1 | 2023 | 34 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2023 | 51 | 0.050 |
Why?
|
| Propidium | 1 | 2022 | 3 | 0.050 |
Why?
|
| Agglutination | 1 | 2022 | 4 | 0.050 |
Why?
|
| Dogs | 1 | 2024 | 326 | 0.050 |
Why?
|
| Immune Sera | 1 | 2022 | 35 | 0.050 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2001 | 72 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2025 | 625 | 0.050 |
Why?
|
| Precipitin Tests | 2 | 1999 | 77 | 0.040 |
Why?
|
| Transfection | 1 | 2003 | 700 | 0.040 |
Why?
|
| Neoplasm Proteins | 2 | 2005 | 286 | 0.040 |
Why?
|
| Cross Protection | 1 | 2021 | 6 | 0.040 |
Why?
|
| Protein Precursors | 2 | 1993 | 85 | 0.040 |
Why?
|
| Fimbriae Proteins | 1 | 2021 | 13 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2005 | 527 | 0.040 |
Why?
|
| Gastric Acid | 1 | 2021 | 9 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2022 | 296 | 0.040 |
Why?
|
| Receptors, Chemokine | 1 | 2000 | 30 | 0.040 |
Why?
|
| Plants, Genetically Modified | 1 | 2021 | 23 | 0.040 |
Why?
|
| Silicon | 1 | 2020 | 17 | 0.040 |
Why?
|
| Porosity | 1 | 2020 | 41 | 0.040 |
Why?
|
| Gelatin | 1 | 2020 | 32 | 0.040 |
Why?
|
| Vero Cells | 1 | 2020 | 81 | 0.040 |
Why?
|
| Immunoconjugates | 1 | 2021 | 95 | 0.040 |
Why?
|
| Bacterial Adhesion | 1 | 2021 | 65 | 0.040 |
Why?
|
| Solubility | 1 | 2020 | 193 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2021 | 190 | 0.040 |
Why?
|
| Phylogeny | 1 | 2021 | 400 | 0.040 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2020 | 89 | 0.040 |
Why?
|
| Aotidae | 1 | 2020 | 11 | 0.040 |
Why?
|
| Intestine, Small | 1 | 2020 | 84 | 0.040 |
Why?
|
| Phosphates | 1 | 2020 | 104 | 0.040 |
Why?
|
| Complement System Proteins | 2 | 1998 | 110 | 0.040 |
Why?
|
| Transformation, Genetic | 1 | 1999 | 31 | 0.040 |
Why?
|
| Antibodies, Blocking | 1 | 1999 | 39 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2023 | 1172 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2010 | 3170 | 0.040 |
Why?
|
| Genotype | 1 | 2021 | 676 | 0.040 |
Why?
|
| Binding, Competitive | 3 | 1994 | 96 | 0.040 |
Why?
|
| Lung | 1 | 2004 | 969 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2020 | 465 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1999 | 365 | 0.040 |
Why?
|
| Drug Stability | 1 | 2019 | 145 | 0.040 |
Why?
|
| Middle Aged | 5 | 2024 | 18501 | 0.040 |
Why?
|
| Polysaccharides | 1 | 2000 | 155 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2021 | 414 | 0.040 |
Why?
|
| Drug Compounding | 1 | 2019 | 80 | 0.040 |
Why?
|
| Receptors, Cytokine | 1 | 1998 | 13 | 0.040 |
Why?
|
| Thrombopoietin | 1 | 1998 | 11 | 0.040 |
Why?
|
| Megakaryocytes | 1 | 1998 | 19 | 0.040 |
Why?
|
| Immunoglobulin Light Chains | 1 | 1998 | 16 | 0.040 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 1990 | 111 | 0.030 |
Why?
|
| Vaccination | 1 | 2001 | 388 | 0.030 |
Why?
|
| Reassortant Viruses | 1 | 1998 | 10 | 0.030 |
Why?
|
| Massachusetts | 1 | 2024 | 2158 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2020 | 617 | 0.030 |
Why?
|
| Hematopoiesis | 1 | 1998 | 128 | 0.030 |
Why?
|
| Multiple Myeloma | 1 | 2003 | 375 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2006 | 2500 | 0.030 |
Why?
|
| Chimera | 3 | 2003 | 44 | 0.030 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 2 | 2009 | 281 | 0.030 |
Why?
|
| Spleen | 2 | 1990 | 476 | 0.030 |
Why?
|
| Cinnamates | 1 | 1996 | 9 | 0.030 |
Why?
|
| Antimetabolites | 1 | 1996 | 18 | 0.030 |
Why?
|
| Ganciclovir | 1 | 1996 | 18 | 0.030 |
Why?
|
| Recurrence | 2 | 2006 | 665 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1998 | 344 | 0.030 |
Why?
|
| Ebola Vaccines | 1 | 2016 | 2 | 0.030 |
Why?
|
| Democratic Republic of the Congo | 1 | 2016 | 19 | 0.030 |
Why?
|
| Antigen-Antibody Complex | 1 | 2016 | 52 | 0.030 |
Why?
|
| Drug Synergism | 3 | 2001 | 142 | 0.030 |
Why?
|
| Burkitt Lymphoma | 1 | 1996 | 74 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2016 | 110 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2016 | 147 | 0.030 |
Why?
|
| Survivors | 1 | 2016 | 189 | 0.030 |
Why?
|
| Aged | 3 | 2024 | 15147 | 0.030 |
Why?
|
| Receptors, HIV | 1 | 1994 | 16 | 0.030 |
Why?
|
| ErbB Receptors | 2 | 2005 | 128 | 0.030 |
Why?
|
| Mutation | 2 | 2020 | 2675 | 0.030 |
Why?
|
| AIDS-Related Complex | 1 | 1993 | 3 | 0.030 |
Why?
|
| Viral Load | 2 | 2006 | 230 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 1993 | 102 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2013 | 51 | 0.020 |
Why?
|
| Clone Cells | 2 | 1990 | 111 | 0.020 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2013 | 29 | 0.020 |
Why?
|
| Vaccines, Synthetic | 1 | 1993 | 80 | 0.020 |
Why?
|
| Child | 1 | 2023 | 4653 | 0.020 |
Why?
|
| G(M1) Ganglioside | 1 | 1992 | 12 | 0.020 |
Why?
|
| Radiation Chimera | 1 | 1992 | 61 | 0.020 |
Why?
|
| Kinetics | 2 | 1993 | 758 | 0.020 |
Why?
|
| Epidermal Growth Factor | 2 | 2005 | 49 | 0.020 |
Why?
|
| Lymphocytes | 1 | 1993 | 210 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 1992 | 116 | 0.020 |
Why?
|
| CD40 Ligand | 2 | 2005 | 159 | 0.020 |
Why?
|
| Major Histocompatibility Complex | 1 | 1992 | 85 | 0.020 |
Why?
|
| Pregnancy | 4 | 2001 | 2401 | 0.020 |
Why?
|
| Antigens, Protozoan | 2 | 1989 | 67 | 0.020 |
Why?
|
| SAIDS Vaccines | 1 | 2011 | 21 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 4883 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2006 | 899 | 0.020 |
Why?
|
| Vagina | 1 | 2011 | 87 | 0.020 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1992 | 185 | 0.020 |
Why?
|
| CD8 Antigens | 1 | 1990 | 53 | 0.020 |
Why?
|
| DNA | 2 | 1992 | 853 | 0.020 |
Why?
|
| Immunoassay | 1 | 2010 | 71 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 1992 | 755 | 0.020 |
Why?
|
| Superoxides | 1 | 1989 | 73 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 1989 | 40 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 1989 | 83 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 1989 | 185 | 0.020 |
Why?
|
| Erythrocytes | 1 | 1990 | 147 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2005 | 1030 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1993 | 642 | 0.020 |
Why?
|
| Plasmodium yoelii | 1 | 1989 | 6 | 0.020 |
Why?
|
| Immunotherapy, Adoptive | 1 | 1990 | 105 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 1996 | 852 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 1989 | 328 | 0.020 |
Why?
|
| Cell Survival | 1 | 1990 | 588 | 0.020 |
Why?
|
| Alanine | 1 | 2008 | 49 | 0.020 |
Why?
|
| Cytokines | 2 | 2005 | 965 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 2010 | 154 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2008 | 157 | 0.020 |
Why?
|
| Synchrotrons | 1 | 2007 | 4 | 0.020 |
Why?
|
| Asparagine | 1 | 2007 | 25 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2010 | 325 | 0.020 |
Why?
|
| Hydrogen Bonding | 1 | 2007 | 128 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2007 | 137 | 0.020 |
Why?
|
| Desmogleins | 1 | 2006 | 2 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2007 | 261 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2006 | 71 | 0.020 |
Why?
|
| Virulence | 1 | 2007 | 199 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2001 | 1439 | 0.020 |
Why?
|
| Viremia | 1 | 2006 | 46 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2006 | 58 | 0.020 |
Why?
|
| Remission Induction | 1 | 2006 | 149 | 0.020 |
Why?
|
| Intradermal Tests | 1 | 2006 | 3 | 0.020 |
Why?
|
| Acantholysis | 1 | 2006 | 5 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2006 | 37 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2007 | 491 | 0.010 |
Why?
|
| Rituximab | 1 | 2006 | 89 | 0.010 |
Why?
|
| Complement C3 | 1 | 2006 | 61 | 0.010 |
Why?
|
| Crystallography | 1 | 2005 | 26 | 0.010 |
Why?
|
| Mice, Nude | 1 | 1986 | 287 | 0.010 |
Why?
|
| Antibodies | 1 | 1986 | 188 | 0.010 |
Why?
|
| Prostaglandins | 1 | 2005 | 18 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2006 | 462 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 2005 | 40 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2006 | 579 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2007 | 488 | 0.010 |
Why?
|
| Staphylococcal Infections | 1 | 2006 | 131 | 0.010 |
Why?
|
| Cell Communication | 1 | 2005 | 135 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2005 | 234 | 0.010 |
Why?
|
| Africa | 1 | 2003 | 30 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2005 | 554 | 0.010 |
Why?
|
| Human Immunodeficiency Virus Proteins | 1 | 2002 | 6 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2005 | 963 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2005 | 378 | 0.010 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 2002 | 21 | 0.010 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2001 | 11 | 0.010 |
Why?
|
| Virus Shedding | 1 | 2001 | 17 | 0.010 |
Why?
|
| Macaca | 1 | 2001 | 30 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2003 | 396 | 0.010 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2001 | 32 | 0.010 |
Why?
|
| Virus Assembly | 1 | 2001 | 54 | 0.010 |
Why?
|
| Delivery, Obstetric | 1 | 2001 | 62 | 0.010 |
Why?
|
| Lactation | 1 | 2001 | 77 | 0.010 |
Why?
|
| Receptors, CXCR4 | 1 | 2000 | 43 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 1573 | 0.010 |
Why?
|
| Receptors, CCR5 | 1 | 2000 | 59 | 0.010 |
Why?
|
| Cesarean Section | 1 | 2001 | 104 | 0.010 |
Why?
|
| Apoptosis | 1 | 2005 | 1100 | 0.010 |
Why?
|
| Transforming Growth Factor alpha | 1 | 1999 | 15 | 0.010 |
Why?
|
| Postpartum Period | 1 | 2001 | 190 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1999 | 194 | 0.010 |
Why?
|
| Receptors, Thrombopoietin | 1 | 1998 | 4 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 1998 | 26 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1998 | 97 | 0.010 |
Why?
|
| Cell Division | 1 | 1999 | 451 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1998 | 178 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1999 | 859 | 0.010 |
Why?
|
| Hygromycin B | 1 | 1996 | 2 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 1999 | 432 | 0.010 |
Why?
|
| Thymidine Kinase | 1 | 1996 | 18 | 0.010 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 1996 | 19 | 0.010 |
Why?
|
| Simplexvirus | 1 | 1996 | 26 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1996 | 167 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1996 | 48 | 0.010 |
Why?
|
| Half-Life | 1 | 1996 | 81 | 0.010 |
Why?
|
| Adolescent | 1 | 2006 | 6368 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1996 | 193 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2003 | 3340 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 1996 | 690 | 0.010 |
Why?
|
| HIV Envelope Protein gp160 | 1 | 1993 | 4 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1995 | 606 | 0.010 |
Why?
|
| Vaccinia virus | 1 | 1993 | 69 | 0.010 |
Why?
|
| Membrane Fusion | 1 | 1993 | 67 | 0.010 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 1992 | 4 | 0.010 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 1992 | 10 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 1992 | 41 | 0.010 |
Why?
|
| Biomarkers | 1 | 1995 | 1503 | 0.000 |
Why?
|
| Transcription Factors | 1 | 1996 | 1561 | 0.000 |
Why?
|